Vaxcyte, Inc. $PCVX Shares Acquired by Corient Private Wealth LP

Corient Private Wealth LP lifted its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 866.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 36,894 shares of the company's stock after buying an additional 33,076 shares during the quarter. Corient Private Wealth LP's holdings in Vaxcyte were worth $2,145,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Jupiter Topco LLC acquired a new position in Vaxcyte in the 2nd quarter valued at about $1,044,355,000. Janus Henderson Group PLC grew its holdings in shares of Vaxcyte by 23.8% in the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company's stock valued at $960,231,000 after purchasing an additional 3,188,687 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Vaxcyte in the second quarter valued at approximately $701,520,000. T. Rowe Price Investment Management Inc. grew its holdings in shares of Vaxcyte by 35.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company's stock valued at $521,213,000 after purchasing an additional 2,981,038 shares in the last quarter. Finally, Wellington Management Group LLP increased its stake in Vaxcyte by 24.7% during the 2nd quarter. Wellington Management Group LLP now owns 7,001,565 shares of the company's stock worth $407,001,000 after buying an additional 1,386,968 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Insiders Place Their Bets

In related news, CFO Andrew Guggenhime sold 10,000 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $53.89, for a total value of $538,900.00. Following the completion of the transaction, the chief financial officer directly owned 105,176 shares of the company's stock, valued at $5,667,934.64. This represents a 8.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Grant Pickering sold 2,000 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $55.65, for a total transaction of $111,300.00. Following the completion of the transaction, the chief executive officer owned 133,215 shares in the company, valued at $7,413,414.75. This represents a 1.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 90,127 shares of company stock worth $5,021,389 in the last three months. 3.30% of the stock is owned by company insiders.

Vaxcyte Trading Down 4.3%

Vaxcyte stock opened at $56.49 on Thursday. The company has a fifty day simple moving average of $58.56 and a 200-day simple moving average of $56.20. The stock has a market cap of $8.41 billion, a P/E ratio of -7.40 and a beta of 1.22. Vaxcyte, Inc. has a 12-month low of $31.89 and a 12-month high of $65.00.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, beating analysts' consensus estimates of ($2.06) by $0.09. During the same period last year, the firm earned ($1.22) earnings per share. As a group, sell-side analysts forecast that Vaxcyte, Inc. will post -7.6 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on PCVX. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vaxcyte in a research report on Monday, July 6th. Zacks Research upgraded Vaxcyte from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 12th. Finally, Wall Street Zen raised Vaxcyte from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 8th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $98.00.

Vaxcyte Profile

Vaxcyte, Inc is a clinical-stage biotechnology company focused on developing vaccines to prevent serious bacterial infections. The company's lead programs target pneumococcal disease, which can cause pneumonia, meningitis, bloodstream infections and other invasive illnesses. Vaxcyte is developing broad-spectrum pneumococcal conjugate vaccine candidates designed to protect against a wide range of bacterial serotypes.

Vaxcyte's pipeline has included VAX-24, an investigational 24-valent pneumococcal conjugate vaccine, and VAX-31, a next-generation candidate designed to cover 31 serotypes.

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.